Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 13/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523486 | 0.86 | MAPK14 (0.57) | MAPK14RIPK2LCKCSF1RKDR | |
| SCHEMBL2215164 | 0.86 | MAPK14 (0.54) | MAPK14CYP2C9 | |
| SCHEMBL2213662 | 0.83 | MAPK14 (0.46) | MAPK14CYP2C9RIPK2 | |
| SCHEMBL5247399 | 0.82 | ABL1 (0.53) | MAPK14RIPK2LCKCSF1RKDR | |
| SCHEMBL2213467 | 0.82 | MAPK14 (0.54) | MAPK14CYP2C9RIPK2LCKCSF1R | |
| SCHEMBL2216662 | 0.80 | KHK (0.57) | MAPK14CYP2C9RIPK2LCKKDR | |
| SCHEMBL2216168 | 0.77 | MAPK14 (0.66) | MAPK14CYP2C9RIPK2LCKKDR | |
| SCHEMBL3520197 | 0.76 | MAPK14 (0.60) | MAPK14RIPK2LCKCSF1RKDR | |
| SCHEMBL3526945 | 0.75 | MAPK13 (0.53) | MAPK14CYP2C9 | |
| SCHEMBL3520802 | 0.75 | MAPK14 (0.59) | MAPK14RIPK2LCKCSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | claimed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | claimed |
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885CYP2C9 2372/4885RIPK2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.